Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
CMPI was delisted on the 27th of May, 2022.
26 hedge funds and large institutions have $54.8M invested in Checkmate Pharmaceuticals, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 9 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
18% more capital invested
Capital invested by funds: $46.3M → $54.8M (+$8.48M)
4% more funds holding
Funds holding: 25 → 26 (+1)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
67% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
+$41.9K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.58K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$3.47K |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$1.56K |
| 5 |
State Street
Boston,
Massachusetts
|
+$969 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
-$486K |
| 2 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
-$268K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$67.4K |
| 4 |
Millennium Management
New York
|
-$31K |
| 5 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$23.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Bank of America
Charlotte,
North Carolina
| – | -$3.19K | -1,111 | -100% |
|
27
JP Morgan Chase
New York
| – | +$141 | +49 | New |
|
CMPI Hedge Fund Activity: Q1 2022 in Review
26 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Checkmate Pharmaceuticals, Inc. Common Stock (CMPI) for Q1 2022, worth a combined $54.8M — up 18% from $46.3M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new CMPI positions and 3 closed out — a net gain of 1 holder — while 3 added to existing stakes and 9 trimmed.
The largest buyer was Barclays, opening a new position worth an estimated $41.9K. The largest seller was Clough Capital Partners, cutting an estimated $486K.
- 26 institutional investors held Checkmate Pharmaceuticals, Inc. Common Stock (CMPI) as of Q1 2022, up from 25 in Q4 2021.
- Funds reported $54.8M of Checkmate Pharmaceuticals, Inc. Common Stock stock for Q1 2022, up 18% quarter-over-quarter.
- 4 funds opened new Checkmate Pharmaceuticals, Inc. Common Stock positions in Q1 2022 and 3 closed out, a net change of +1 holder.
- The largest Checkmate Pharmaceuticals, Inc. Common Stock buyer in Q1 2022 was Barclays, an estimated $41.9K added.
- The largest Checkmate Pharmaceuticals, Inc. Common Stock seller in Q1 2022 was Clough Capital Partners, an estimated $486K sold.
Based on aggregated 13F filings for Q1 2022.